Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Mesoblast Limited ( (AU:MSB) ) is now available.
Mesoblast director Gregory George has significantly increased his stake in the company through a series of on-market purchases of ordinary shares and American Depositary Shares in early March 2026. The total consideration for these acquisitions was about US$16.4 million, underscoring a substantial show of confidence in the company’s prospects from a key insider.
Following the transactions, George’s indirect holdings rose to 5,644,192 ordinary shares and 27,015,410 ADS, alongside existing warrants to acquire additional ordinary shares. Some previously held ordinary shares were converted into ADS without altering his underlying economic interest, consolidating his exposure and potentially signaling long-term alignment with other shareholders.
The most recent analyst rating on (AU:MSB) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited is a biotechnology company focused on developing and commercializing regenerative medicine therapies. The company’s primary products are based on mesenchymal lineage adult stem cells, targeting inflammatory and immune-mediated diseases across global markets, with its securities listed on the Australian Securities Exchange and represented in part by American Depositary Shares.
YTD Price Performance: -15.44%
Average Trading Volume: 4,135,847
Technical Sentiment Signal: Hold
Current Market Cap: A$2.97B
For a thorough assessment of MSB stock, go to TipRanks’ Stock Analysis page.